Literature DB >> 15675980

Pentoxifylline attenuates the increase in whole blood viscosity after transfusion.

A Bacher1, E Eggensperger, R Koppensteiner, N Mayer, W Klimscha.   

Abstract

BACKGROUND: Pentoxifylline improves tissue oxygenation and intestinal blood flow in models of haemorrhagic shock, and it has been used for the treatment of intermittent claudication due to its beneficial effects on haemorheology. We investigated the effects of pentoxifylline on whole blood viscosity during packed red-blood cell transfusion in critically ill adult patients.
METHODS: Twenty critically ill patients were randomly assigned to one of two groups (pentoxifylline group: n = 11, placebo group: n = 9) and prospectively studied. Forty-five minutes before and during the packed red-blood cell transfusion (10 ml min(-1)) over a period of 80 min, 1.5 mg kg(-1) . h(-1) pentoxifylline or placebo were administered intravenously. Haematocrit, plasma fibrinogen concentration, total protein concentration, whole blood viscosity (at a shear rate of 10 s(-1), 50 s(-1), and 100 s(-1)) and plasma viscosity were measured.
RESULTS: After the packed red-blood cell transfusion, haematocrit levels increased significantly in both groups (pentoxifylline group: from 26.1 +/- 2.8% to 33.0 +/- 3.2; placebo group: from 24.4 +/- 3.3% to 32.6 +/- 2.6%; means +/- standard deviation). Compared to baseline, whole blood viscosity increased in both groups at all shear rates after the transfusion, but the increase was significantly less in the pentoxifylline group (26 +/- 15% vs. 49 +/- 14%, 23 +/- 11% vs. 39 +/- 12%, and 22 +/- 11% vs. 35 +/- 12% for the pentoxifylline vs. placebo groups at shear rates of 10 s(-1), 50 s(-1), and 100 s(-1), respectively). Plasma viscosity, total protein concentration, and fibrinogen concentration remained unchanged and no significant differences among groups were observed.
CONCLUSIONS: These results suggest that pentoxifylline is effective in attenuating the increase in whole blood viscosity after a transfusion of packed red-blood cells. Plasma viscosity is not influenced by pentoxifylline.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15675980     DOI: 10.1111/j.1399-6576.2004.00547.x

Source DB:  PubMed          Journal:  Acta Anaesthesiol Scand        ISSN: 0001-5172            Impact factor:   2.105


  3 in total

1.  Pentoxifylline treatment and penile calcifications in men with Peyronie's disease.

Authors:  James F Smith; Alan W Shindel; Yun-Ching Huang; Raul I Clavijo; Lawrence Flechner; Benjamin N Breyer; Michael L Eisenberg; Tom F Lue
Journal:  Asian J Androl       Date:  2010-11-22       Impact factor: 3.285

2.  Pharmacological studies on the anti-inflammatory and immunomodulatory role of pentoxifylline and its interaction with nitric oxide (NO) in experimental arthritis in rats.

Authors:  Rishi Pal; Manju J Chaudhary; Prafulla Chandra Tiwari; Rajendra Nath; Suresh Babu; Kamlesh Kumar Pant
Journal:  Inflammopharmacology       Date:  2016-09-26       Impact factor: 4.473

3.  Immunotherapeutic effects of pentoxifylline in type 1 diabetic mice and its role in the response of T-helper lymphocytes.

Authors:  Farin Malekifard; Nowruz Delirezh; Rahim Hobbenaghi; Hassan Malekinejad
Journal:  Iran J Basic Med Sci       Date:  2015-03       Impact factor: 2.699

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.